Comment on

• Randomized trial of lifestyle modification and pharmacotherapy for obesity.

  Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Phelan S, Cato RK, Hesson LA, Osei SY, Kaplan R, Stunkard AJ. Wadden TA, et al. N Engl J Med. 2005 Nov 17;353(20):2111-20. doi: 10.1056/NEJMoa050156. N Engl J Med. 2005. PMID: 16291981 Clinical Trial.
• Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.

  Després JP, Golay A, Sjöström L; Rimonabant in Obesity-Lipids Study Group. Després JP, et al. N Engl J Med. 2005 Nov 17;353(20):2121-34. doi: 10.1056/NEJMoa044537. N Engl J Med. 2005. PMID: 16291982 Clinical Trial.